- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic vaccination to treat chronic infectious diseases
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 8, Issue 12, Pages 1746-1757
Publisher
Informa UK Limited
Online
2012-10-24
DOI
10.4161/hv.21689
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
- (2012) Christoph Welsch et al. GUT
- Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination
- (2012) Céline Verheust et al. VACCINE
- Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy
- (2011) Jean-Luc Brun et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Human papillomavirus in head and neck cancers
- (2011) Amanda Psyrri et al. ANTI-CANCER DRUGS
- Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells
- (2011) Christin Flechsig et al. CYTOTHERAPY
- Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges
- (2011) Marie-Louise Michel et al. JOURNAL OF HEPATOLOGY
- Cytosolic DNA Triggers Mitochondrial Apoptosis via DNA Damage Signaling Proteins Independently of AIM2 and RNA Polymerase III
- (2011) M. Wenzel et al. JOURNAL OF IMMUNOLOGY
- Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
- (2011) Paul A. Goepfert et al. JOURNAL OF INFECTIOUS DISEASES
- Interplay between Modified Vaccinia Virus Ankara and Dendritic Cells: Phenotypic and Functional Maturation of Bystander Dendritic Cells
- (2011) M. F. Pascutti et al. JOURNAL OF VIROLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tuberculosis vaccines: beyond bacille Calmette-Guerin
- (2011) H. McShane PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection
- (2011) James S. Cavenaugh et al. PLoS One
- Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8+ T Cell Responses in HIV-1-Infected Individuals
- (2011) Núria Climent et al. PLoS One
- Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
- (2011) M. O. C. Ota et al. Science Translational Medicine
- RNA species generated in vaccinia virus infected cells activate cell type-specific MDA5 or RIG-I dependent interferon gene transcription and PKR dependent apoptosis
- (2011) Chad Myskiw et al. VIROLOGY
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- Preclinical Studies of a Modified Vaccinia Virus Ankara-Based HIV Candidate Vaccine: Antigen Presentation and Antiviral Effect
- (2010) S. Brandler et al. JOURNAL OF VIROLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, inMycobacterium tuberculosis–infected Individuals
- (2009) Clare R. Sander et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Global Burden and Epidemiology of Tuberculosis
- (2009) Philippe Glaziou et al. CLINICS IN CHEST MEDICINE
- Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
- (2009) Thomas J. Scriba et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Vaccination Against Hepatitis B and C: Towards Therapeutic Application
- (2009) Geneviève Inchauspé et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression
- (2009) M. H. Lehmann et al. JOURNAL OF VIROLOGY
- AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
- (2009) Veit Hornung et al. NATURE
- Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands
- (2009) Roman Barbalat et al. NATURE IMMUNOLOGY
- MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques
- (2009) Frank A. W. Verreck et al. PLoS One
- Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
- (2009) Julie Delaloye et al. PLoS Pathogens
- Dendritic Cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo
- (2008) Luzheng Liu et al. BMC IMMUNOLOGY
- Clinical development of MVA-based therapeutic cancer vaccines
- (2008) Bruce Acres et al. Expert Review of Vaccines
- Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
- (2008) Christofer Samuelsson et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa
- (2008) Tony Hawkridge et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy
- (2008) Thomas C. Greenough et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More